Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRB1 | P17538 | 2/20 | 0.54 |
| ▸ | ELANE | P08246 | 2/20 | 0.53 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.52 |
| ▸ | TACR1 | P25103 | 1/20 | 0.51 |
| ▸ | KYNU | Q16719 | 1/20 | 0.51 |
| ▸ | KLK1 | P06870 | 1/20 | 0.51 |
| ▸ | ECE1 | P42892 | 4/20 | 0.51 |
| ▸ | MME | P08473 | 3/20 | 0.51 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trimethylammonium SCHEMBL28037498 | 0.94 | ELANE (0.52) | CTRB1ELANEACE2KYNUECE1 | |
| SCHEMBL1068881 | 0.90 | KYNU (0.60) | CTRB1ELANEACE2TACR1KYNU | |
| SCHEMBL535707 | 0.84 | KYNU (0.57) | CTRB1ELANEACE2KYNUKLK1 | |
| SCHEMBL13435790 | 0.84 | KYNU (0.57) | CTRB1ELANEACE2KYNUKLK1 | |
| SCHEMBL12903901 | 0.84 | KYNU (0.60) | CTRB1ELANEACE2TACR1KYNU | |
| SCHEMBL7432286 | 0.84 | KYNU (0.60) | CTRB1ACE2TACR1KYNUECE1 | |
| SCHEMBL1110994 | 0.83 | KYNU (0.56) | CTRB1ELANEACE2KYNUKLK1 | |
| SCHEMBL15549899 | 0.82 | ELANE (0.54) | CTRB1ELANEACE2KYNUKLK1 | |
| SCHEMBL4163321 | 0.82 | ELANE (0.60) | CTRB1ELANEACE2KYNUECE1 | |
| SCHEMBL11567174 | 0.82 | ELANE (0.60) | CTRB1ELANEACE2KYNUECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220362386-A1 | LIQUID COMPOSITIONS COMPRISING A LEVODOPA AMINO ACID CONJUGATE AND USES THEREOF | NEURODERM LTD (IL) | 2022-11-17 | — | — | US | disclosed |
| WO-2022191338-A1 | LEVODOPA-PRODRUGS AND CARBIDOPA-PRODRUGS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2022-09-15 | — | — | WO | disclosed |
| EP-4025200-A1 | LIQUID COMPOSITIONS COMPRISING A LEVODOPA AMINO ACID CONJUGATE AND USES THEREOF | Neuroderm Ltd (IL) | 2022-07-13 | — | — | EP | disclosed |
| CN-114727973-A | Liquid compositions comprising L-dopa amino acid conjugates and uses thereof | 纽罗德姆有限公司 | 2022-07-08 | — | — | CN | disclosed |
| US-20210145824-A1 | MODULATORS OF CELLULAR ADHESION | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2021-05-20 | — | — | US | disclosed |
| US-20190134022-A1 | MODULATORS OF CELLULAR ADHESION | SARCODE BIOSCIENCE INC. (US) | 2019-05-09 | — | — | US | disclosed |
| US-10124000-B2 | Modulators of cellular adhesion | SARCODE BIOSCIENCE INC. (US) | 2018-11-13 | — | — | US | disclosed |
| CN-105073755-B | The tetracyclic compound of heterocyclic substituted and its application method for treating viral disease | 默沙东公司 | 2017-08-18 | — | — | CN | disclosed |
| US-20160074381-A1 | MODULATORS OF CELLULAR ADHESION | SARCODE BIOSCIENCE INC. (US) | 2016-03-17 | — | — | US | disclosed |
| US-9248126-B2 | Modulators of cellular adhesion | SARCODE BIOSCIENCE INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-20050267098-A1 | Modulators of cellular adhesion | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT | 2005-12-01 | — | — | US | disclosed |
| EP-1590340-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2005-11-02 | — | — | EP | disclosed |
| EP-1581496-A2 | 2-SUBSTITUTED-3-PROPENAMIDE DERIVATIVES AND METHODS OF USING THE SAME | GILEAD SCIENCES, INC. (US) | 2005-10-05 | — | — | EP | disclosed |
| EP-1554250-A1 | NOVEL LACTAMS AND USES THEREOF | AstraZeneca AB (SE) | 2005-07-20 | — | — | EP | disclosed |
| WO-2005044817-A1 | MODULATORS OF CELLULAR ADHESION | SUNESIS PHARMACEUTICALS, INC. (US) | 2005-05-19 | — | — | WO | disclosed |
| WO-2004069823-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2004-08-19 | — | — | WO | disclosed |
| WO-2004050613-A2 | 2-SUBSTITUTED-3-PROPENAMIDE DERIVATIVES AND METHODS OF USING THE SAME | GILEAD SCIENCES, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
| WO-2004031154-A1 | NOVEL LACTAMS AND USES THEREOF | ASTRAZENECA AB (SE) | 2004-04-15 | — | — | WO | disclosed |
| EP-1305293-A1 | HEXAHYDRO-7-IMINO-1H-AZEPIN-2-YL-HEXANOIC ACID DERIVATIVES AS INHIBITORS OF INDUCIBLE NITRIC OXIDE SYNTHASE | Pharmacia Corporation (US) | 2003-05-02 | — | — | EP | disclosed |
| WO-2002010139-A1 | HEXAHYDRO-7-1H-AZEPIN-2-YL-HAXANOIC ACID DERIVATIVES AS INHIBITORS OF INDUCIBLE NITRIC OXIDE SYNTHASE | PHARMACIA CORPORATION (US) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210145824-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | CTRB1 2060/4885ELANE 202/4885ACE2 4146/4885 |
| US-20220362386-A1 | LIQUID COMPOSITIONS COMPRISING A LEVODOPA AMINO ACID CONJUGATE AND USES THEREOF | DAO, DDC, AADAT | CTRB1 1721/4885ELANE 1080/4885ACE2 2073/4885 |
| US-10124000-B2 | Modulators of cellular adhesion | ITGB1, VCAM1, ITGB8 | CTRB1 2060/4885ELANE 202/4885ACE2 4146/4885 |
| US-20050267098-A1 | Modulators of cellular adhesion | ITGB1, VCAM1, ITGB8 | CTRB1 2060/4885ELANE 202/4885ACE2 4146/4885 |
| US-20160074381-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | CTRB1 2060/4885ELANE 202/4885ACE2 4146/4885 |
| US-20190134022-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | CTRB1 2060/4885ELANE 202/4885ACE2 4146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.